Article Figures & Tables
Figures
- Figure 1:
Age-standardized incidence rates (ASIRs) for selected cancers, in Canada (excluding Quebec), 1984–2020, by sex. Shading indicates projected data.
- Figure 2:
Age-standardized mortality rates (ASMRs) for selected cancers in Canada, 1984–2020, by sex. Shading indicates projected data.
Tables
- Table 1:
Projected estimates of new cases and age-standardized incidence rates for cancers in Canada in 2020, by sex
Type of cancer No. of new cases ASIR* Total† Males Females In both sexes Males Females All cancers‡ 225 800 115 800 110 000 519.4 557.8 491.2 Lung and bronchus 29 800 15 000 14 800 61.4 64.8 59.3 Breast 27 700 240 27 400 66.9 1.1 128.2 Colorectal 26 900 14 900 12 000 60.5 71.5 50.8 Prostate 23 300 23 300 NA NA 116.7 NA Bladder§ 12 200 9400 2800 25.0 42.0 10.7 Non-Hodgkin lymphoma 10 400 5800 4500 24.4 29.3 20.2 Thyroid 8600 2300 6400 22.5 11.7 33.1 Melanoma 8000 4400 3600 21.8 25.2 19.2 Kidney and renal pelvis 7500 4900 2600 17.3 23.6 11.5 Uterus (body, NOS) 7400 NA 7400 NA NA 35.0 Leukemia 6900 4100 2800 16.5 21.1 12.6 Pancreas 6000 3100 2900 13.0 14.2 11.8 Oral 5400 3700 1650 12.8 18.5 7.5 Stomach 4200 2700 1450 9.4 13.1 6.1 Multiple myeloma 3400 2000 1450 7.8 9.7 6.1 Ovary 3100 NA 3100 NA NA 14.2 Liver 3100 2300 810 6.8 10.6 3.3 Brain/CNS 3000 1700 1350 7.1 8.3 5.9 Esophagus 2400 1850 550 5.7 9.3 2.4 Cervix 1350 NA 1350 NA NA 7.1 Testis 1150 1150 NA NA 6.5 NA Larynx 1150 980 180 2.3 4.1 0.7 Hodgkin lymphoma 1000 570 440 2.6 2.9 2.3 All other cancers 21 800 11 300 10 500 47.5 53.2 43.2 Note: ASIR = age-standardized incidence rate, CNS = central nervous system, NOS = not otherwise specified, NA = not applicable.
↵* Rates exclude those from Quebec.
↵† Column total may not sum to row totals owing to rounding.
↵‡ All cancers excludes nonmelanoma skin cancers (neoplasms, NOS; epithelial neoplasms, NOS; and basal and squamous).
↵§ Bladder cancer includes in situ carcinomas.
- Table 2:
Projected estimates of deaths and age-standardized mortality rates for cancers in Canada in 2020, by sex
Type of cancer No. of deaths ASMR Total* Males Females Both sexes Males Females All cancers 83 300 44 100 39 300 188 219.7 164.2 Lung and bronchus 21 200 11 000 10 200 47.2 53.4 42.5 Colorectal 9700 5300 4400 21.8 26.4 18.0 Pancreas 5300 2700 2600 12.0 13.5 10.7 Breast 5100 55 5100 11.9 0.3 22.0 Prostate 4200 4200 NA NA 21.8 NA Leukemia 3000 1800 1250 6.9 9.0 5.2 Non-Hodgkin lymphoma 2900 1600 1250 6.5 8.1 5.1 Bladder 2600 1850 720 5.7 9.6 2.8 Brain/CNS 2500 1400 1050 5.8 7.1 4.7 Esophagus 2300 1750 510 5.1 8.6 2.1 Ovary 1950 NA 1950 NA NA 8.3 Stomach 1950 1200 760 4.5 6.0 3.2 Kidney and renal pelvis 1950 1300 680 4.4 6.4 2.8 Multiple myeloma 1600 880 700 3.5 4.4 2.8 Oral 1500 1050 440 3.5 5.3 1.8 Liver† 1450 1150 290 3.2 5.5 1.2 Uterus (body, NOS) 1300 NA 1300 NA NA 5.4 Melanoma 1300 870 450 3.1 4.4 2.0 Cervix 410 NA 410 NA NA 2.0 Larynx 400 330 75 0.9 1.6 0.3 Thyroid 230 110 130 0.5 0.5 0.5 Hodgkin lymphoma 100 65 40 0.2 0.3 0.2 Testis 35 35 NA NA 0.2 NA All other cancers 10 400 5400 5000 23.5 27.3 20.5 Note: ASMR = age-standardized mortality rate, CNS = central nervous system, ICD-10 = International Statistical Classification of Diseases and Related Health Problems, 10th Revision, NA = not applicable, NOS = not otherwise specified.
↵* Column total may not sum to row totals owing to rounding.
↵† Liver cancer mortality was underestimated because deaths from liver cancer, unspecified (ICD-10 code C22.9) were excluded.
In this issue
Article tools
Jump to section
Related Articles
Cited By...
- Avancees dans la prise en charge de ladenocarcinome canalaire pancreatique
- Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T)
- Negative impact of COVID-19 associated health system shutdown on patients diagnosed with colorectal cancer: a retrospective study from a large tertiary center in Ontario, Canada
- Breast Cancer Survival in Multiple Sclerosis: A Matched Cohort Study
- Advances in the management of pancreatic ductal adenocarcinoma
- Association between antihypertensive medications and risk of skin cancer in people older than 65 years: a population-based study
- Depistage du cancer au Canada: Ce qui est in, ce qui est out, ce qui sen vient
- Cancer screening in Canada: Whats in, whats out, whats coming
More in this TOC Section
Similar Articles
